The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
This approval is a significant achievement in expanding the availability of this critical therapeutic,
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Subscribe To Our Newsletter & Stay Updated